IIFL Securities Stock Idea: Buy Piramal Pharma with Target Rs 260

On October 24, IIFL Securities recommended a 'buy' call on Piramal Pharma, with a target price of Rs 260, citing its strong portfolio of brands, including over-the-counter (OTC) and prescribed drugs, as well as its potential for growth in the domestic and export markets. The current market price of Piramal Pharma is Rs 246.78. The brokerage firm believes that the company's focus on chronic and acute therapies, coupled with its investments in research and development, positions it well for future growth.

About Piramal Pharma:

Piramal Pharma Limited (PPL) is a global pharmaceutical company headquartered in Mumbai, India. It operates through three primary business segments: Contract Development and Manufacturing Organization (CDMO), Complex Generics, and India Consumer Products. PPL's CDMO business provides end-to-end solutions for drug development and manufacturing to pharmaceutical and biotechnology companies worldwide. Its Complex Generics division focuses on developing, manufacturing, and distributing specialized generics in the United States and Europe. In India, PPL's Consumer Products division offers a range of over-the-counter (OTC) healthcare and wellness products. With a global footprint spanning over 100 countries, PPL aims to provide affordable and accessible healthcare solutions to patients worldwide.

52 Week Price Trend:

Piramal Pharma (NSE: PPLPHARMA) has seen a significant surge in its stock price, currently trading at Rs 246.78, over 300% higher than its 52-week low of Rs 61.62. This rally has been driven by several factors, including the company's strong financial performance, expansion into new markets, and positive industry tailwinds. Despite its impressive gains, Piramal Pharma still has room for further growth, given its strong fundamentals and the potential for continued growth in the global pharmaceutical market.

Stratzy's MOST Analysis:

PPLPHARMA has received a BB- rating from Stratzy's MOST framework, indicating a medium fundamental risk. This assessment considers the company's management, outlook, safety, and trend. The framework assigns scores to each pillar, resulting in an overall rating ranging from AAA (low risk) to CC- (high risk). PPLPHARMA's BB- rating suggests that while it faces some fundamental challenges, there are also positive aspects to its operations. Investors should carefully consider these factors before making investment decisions.

Fundamental and Technical information provided in this blog were last updated on 24 Oct, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.